Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 2/20 | 0.42 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.42 |
| ▸ | ITGAL | P20701 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3765817 | 1.00 | ITGB2 (0.42) | ITGB2ICAM1ITGALTDP1HCAR2 | |
| SCHEMBL3772235 | 0.92 | TDP1 (0.43) | TDP1HPGDKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL3772240 | 0.92 | TDP1 (0.43) | TDP1HPGDKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL13636365 | 0.90 | HPGD (0.47) | ITGB2ICAM1ITGALHCAR2HPGD | |
| SCHEMBL4377227 | 0.90 | HPGD (0.47) | ITGB2ICAM1ITGALHCAR2HPGD | |
| SCHEMBL14190928 | 0.89 | HCAR2 (0.48) | ITGB2ICAM1ITGALHCAR2HPGD | |
| SCHEMBL4382018 | 0.89 | HCAR2 (0.48) | ITGB2ICAM1ITGALHCAR2HPGD | |
| SCHEMBL3769345 | 0.87 | L3MBTL1 (0.53) | TDP1HPGDKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL3769341 | 0.87 | L3MBTL1 (0.53) | TDP1HPGDKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL3774586 | 0.84 | HPGD (0.60) | TDP1HPGDKDM4EL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | HRH4, HRH3, HRH1 | ITGB2 4002/4885ICAM1 2254/4885ITGAL 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.